Armando Anido

Zynerba Pharmaceuticals R&D Expenses For Q1 Reach $7.1M, Here Are The Details
Zynerba Pharmaceuticals R&D Expenses For FY22 Reach $21.1M, What About Net Loss?
What's The Role Of The Endocannabinoid System In Fragile X Syndrome? How Can Cannabidiol Treatment Help? New Paper
Zynerba Pharmaceuticals R&D Expenses For FY22 Reach $21.1M, What About Net Loss?
What's The Role Of The Endocannabinoid System In Fragile X Syndrome? How Can Cannabidiol Treatment Help? New Paper
CBD-Based Zygel Helps With Anxiety-Related & Behavioral Symptoms In 22q11.2 Deletion Syndrome, Phase 2 Trial Reveals
Zynerba Pharmaceuticals R&D Expanses For Q2 Reach 5.4M, Here Are The Details

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2024 Benzinga | All Rights Reserved